- Home
- LNW vs EXAS Comparison
LNW vs EXAS Comparison
Compare LNW & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNW
- EXAS
- Stock Information
- Founded
- LNW 1984
- EXAS 1995
- Country
- LNW United States
- EXAS United States
- Employees
- LNW N/A
- EXAS N/A
- Industry
- LNW EDP Services
- EXAS Medical Specialities
- Sector
- LNW Technology
- EXAS Health Care
- Exchange
- LNW Nasdaq
- EXAS Nasdaq
- Market Cap
- LNW 8.5B
- EXAS 9.1B
- IPO Year
- LNW N/A
- EXAS N/A
- Fundamental
- Price
- LNW $78.86
- EXAS $40.99
- Analyst Decision
- LNW Buy
- EXAS Strong Buy
- Analyst Count
- LNW 11
- EXAS 22
- Target Price
- LNW $108.18
- EXAS $67.62
- AVG Volume (30 Days)
- LNW 989.4K
- EXAS 3.4M
- Earning Date
- LNW 08-06-2025
- EXAS 08-06-2025
- Dividend Yield
- LNW N/A
- EXAS N/A
- EPS Growth
- LNW 19.32
- EXAS N/A
- EPS
- LNW 3.95
- EXAS N/A
- Revenue
- LNW $3,195,000,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- LNW $8.88
- EXAS $14.61
- Revenue Next Year
- LNW $7.69
- EXAS $12.71
- P/E Ratio
- LNW $19.97
- EXAS N/A
- Revenue Growth
- LNW 3.83
- EXAS 12.55
- 52 Week Low
- LNW $69.56
- EXAS $38.81
- 52 Week High
- LNW $115.00
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- LNW 26.57
- EXAS 24.55
- Support Level
- LNW $69.56
- EXAS $38.81
- Resistance Level
- LNW $99.99
- EXAS $48.24
- Average True Range (ATR)
- LNW 3.31
- EXAS 2.04
- MACD
- LNW -2.40
- EXAS -0.57
- Stochastic Oscillator
- LNW 30.18
- EXAS 18.71
About LNW Light & Wonder Inc.
Light & Wonder is principally an electronic gaming machine manufacturer, selling machines to pubs, clubs, and casinos. The firm is licensed in most jurisdictions allowing gambling globally. Light & Wonder is one of the three largest players in the space along with International Game Technology and Aristocrat Leisure. SciPlay, about one fourth of revenue, develops and distributes casual mobile games, principally in the social casino niche. The more nascent iGaming business sits between these two businesses, providing digital content and capabilities to real-money gaming providers.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.